Christoph Schaefer

Christoph Schaefer

Auto-generated profile, based on publicly available information

Christoph Schaefer

Department of Dermatology, Venereology and Allergology, University-Hospital Essen, University of Duisburg-Essen, Essen, Germany

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2017 in Journal of Medical Internet Research
Verified
Journal Article
Open access
TBTitus Josef Brinker
Titus Josef Brinker
CBChristian Martin Brieske
Christian Martin Brieske
CSChristoph Matthias Schaefer
Christoph Matthias Schaefer
FBFabian Buslaff
Fabian Buslaff
MGMartina Gatzka
Martina Gatzka
JKJoachim Klode
Joachim Klode
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

1 June 2006 in Anesthesiology
Verified
Journal Article
Open access
TGThierry Girard
Thierry Girard
MJMartin Jöhr
Martin Jöhr
CSChristoph Schaefer
Christoph Schaefer
AUAlbert Urwyler
Albert Urwyler

1 January 1997 in European Surgical Research
Verified
Journal Article
Closed access
PDF file
MZM. Zuber
M. Zuber
GSG.C. Spagnoli
G.C. Spagnoli
TKT. Kocher
T. Kocher
ULU. LÜScher
U. LÜScher
CSC. Schaefer
C. Schaefer
MHM. Heberer
M. Heberer
Objective: The authors’ objective is to identify MAGE-1 tumor antigen in clinical melanoma specimens and to verify the extent of its expression in tumors where evidence of specific gene transcripts can be obtained. Background data: The MAGE-1 gene encodes a tumor-associated antigen that can be recognized by specific cytotoxic T lymphocytes. Transcription of the MAGE-1 gene has previously been demonstrated in various malignancies, but the production of the specific gene product and its distribution in neoplastic tissues have not yet been addressed. Methods: Total cellular mRNA was extracted from six melanoma biopsies, reverse-transcribed and tested in 25-45 cycles of reverse polymerase chain reaction (rtPCR) in the presence of primers’ pairs specific for the β-actin-positive control gene and for the MAGE-1 -encoding gene. Concurrently, portions of these specimens were lysed and probed for MAGE-1 protein by immunoblotting. Additional material from the same biopsies was analyzed following immunohistological staining with MAGE-1-specific monoclonal antibodies. Results: MAGE-1 gene transcription could be demonstrated following 25 cycles of rtPCR in one out of six biopsies and in three more following 35 cycles of rtPCR. 2/6 samples were negative even after 45 cycles of rtPCR. MAGE-1 protein production could be detected by immunoblotting in the lysates from biopsies showing evidence of specific gene transcription. Cells positive for MAGE-1 protein expression could be identified by immunohistochemistry on snap-frozen sections in three of the four tumors displaying specific transcripts. Distribution of positivity ranged between focal cellular areas and single positive cells in the different tumors. Conclusions: The MAGE-1 tumor antigen can be detected by specific monoclonal antibodies in clinical tumor specimens. The pattern of positivity observed in samples showing evidence of MAGE-1 gene expression suggests a relevant heterogeneity regarding MAGE-1 antigen production within individual tumor specimens.